Search

everythinglearnresearchcommunity

for

Search:↓

Noninvasive treatments like PRP and laser therapy can effectively promote hair growth and reduce hair loss.

Sex hormones affect hair growth and loss, and treatments for related hair diseases include various medications, hair transplantation, and light therapy.

Scalp microinfusion is a new method for treating hair loss that shows promise but needs more research for standardization.

Mohamed Kandil suggests renaming Polycystic Ovary Syndrome to "Polyfollicular Anovulatory Androgenic Syndrome" to better describe its symptoms, but concerns exist that it may not cover all related issues like obesity and depression.

Hair loss can be managed with treatments like minoxidil, finasteride, and others, but there are still gaps in effectiveness and off-label usage is increasing.

The review provided information on various treatments to stop hair thinning and increase hair density in people with common genetic hair loss.

Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.

Minoxidil and finasteride are effective for male hair loss; minoxidil also helps female hair loss, with some treatments needing more research.

Hormonal therapy like cyproterone acetate and spironolactone may help female hair loss, but more research is needed, especially for pre-menopausal women.

Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.

Female pattern hair loss is common and should be treated early to prevent worsening, with Minoxidil being the main approved treatment.

More research is needed to find effective treatments for Female Pattern Hair Loss.

Topical minoxidil is the best-supported treatment for female hair loss, but personalized plans are needed.

The document doesn't provide enough information to summarize.

The study found that certain microRNAs are higher in the cells and lower in the fluid of women with a specific type of polycystic ovary syndrome, and one microRNA could potentially help diagnose the condition.

Flibanserin's effectiveness for low sexual desire in premenopausal women may vary based on hormone levels, with normal hormone levels showing better responses.

Certain microRNAs in the fluid around eggs are linked to Polycystic Ovary Syndrome and may help diagnose it.

Spironolactone may cause sexual pain and arousal issues in women, which can improve after stopping the drug and using hormone cream.

PCOS is a common hormonal disorder in women, marked by symptoms like hair growth and menstrual issues, and requires personalized treatment.

Shorter CAG repeats in a specific gene may increase male hormone activity and symptoms like acne and excess hair in women with PCOS.

Hormones affect skin aging and fat distribution, and treatments can help, but only minoxidil is proven for female hair loss.

Skin problems in PCOS, like excess hair, acne, and hair loss, may not always indicate high male hormone levels and need careful diagnosis for proper treatment.

The document concludes that more research is needed to include new treatments in guidelines for Polycystic Ovary Syndrome (PCOS).

Drinking alcohol before taking flibanserin does not increase the risk of severe low blood pressure or fainting.

5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.

Both minoxidil-spironolactone and minoxidil-finasteride treatments work for hair loss, but minoxidil-spironolactone is slightly more effective, especially in women.

Different types of female pattern hair loss have unique characteristics and are associated with various health conditions.

The study found that women with PCOS have more and larger ovarian follicles and differences in ovarian structure, but these features alone can't always diagnose PCOS.